Tenderwize
Retour à la recherche

Open-house rebate agreement for Relugolix

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 431 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Relugolix, ATC L02BX04

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Submitting documents through the wrong portal area is explicitly prohibited; the contract documents must be sent via th...

The latest contract conclusion date is 03.11.2027, and monthly cut-offs apply for next-month start dates.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive open-house rebate agreements for the active substance Relugolix, ATC L02BX04.
  • Supply of pharmaceutical products under a pre-defined contract model with no individual negotiation.
Afficher le résumé complet

Open-house supply arrangement for pharmaceutical products concerning Relugolix (ATC L02BX04) by AOK Bayern. The model is explicitly described as non-exclusive and open to all interested pharmaceutical companies that meet the stated suitability requirement. No estimated contract value is provided. Submission is via DTVP electronic portal with a qualified electronic signature or by paper originals in duplicate; the latest contract conclusion date is 03.11.2027, while the overall contract period runs from 01.01.2026 to 31.12.2027.

Risques

Submitting documents through the wrong portal area is explicitly prohibited; the contract documents must be sent via th...

The latest contract conclusion date is 03.11.2027, and monthly cut-offs apply for next-month start dates.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Relugolix

Single lot for non-exclusive open-house rebate agreements for the medicinal product Relugolix, ATC L02BX04. Scope is pharmaceutical supplies in Germany (place of performance: DE212 / Bavaria). The lot information comes from structured data and XML notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 03, 2027

Détails de la procédure

Date de publication
16 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
761915-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30